News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
545,011 Results
Type
Article (39735)
Company Profile (74)
Press Release (505202)
Multimedia
Podcasts (45)
Webinars (11)
Section
Business (151684)
Career Advice (2430)
Deals (27672)
Drug Delivery (98)
Drug Development (72781)
Employer Resources (141)
FDA (13599)
Job Trends (12197)
News (270836)
Policy (26939)
Tag
Academia (2532)
Academic (1)
Accelerated approval (5)
Adcomms (26)
Allergies (80)
Alliances (38312)
ALS (95)
Alzheimer's disease (1395)
Antibody-drug conjugate (ADC) (135)
Approvals (13588)
Artificial intelligence (243)
Autoimmune disease (23)
Automation (16)
Bankruptcy (309)
Best Places to Work (9994)
BIOSECURE Act (15)
Biosimilars (91)
Biotechnology (61)
Bladder cancer (80)
Brain cancer (26)
Breast cancer (275)
Cancer (2187)
Cardiovascular disease (189)
Career advice (2042)
Career pathing (32)
CAR-T (146)
Cell therapy (403)
Cervical cancer (17)
Clinical research (59493)
Collaboration (723)
Company closure (2)
Compensation (290)
Complete response letters (22)
COVID-19 (2464)
CRISPR (40)
C-suite (261)
Cystic fibrosis (84)
Data (2207)
Decentralized trials (2)
Denatured (6)
Depression (52)
Diabetes (260)
Diagnostics (5715)
Digital health (14)
Diversity (4)
Diversity, equity & inclusion (38)
Drug discovery (111)
Drug pricing (95)
Drug shortages (23)
Duchenne muscular dystrophy (92)
Earnings (55055)
Editorial (40)
Employer branding (18)
Employer resources (128)
Events (74798)
Executive appointments (731)
FDA (14844)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (670)
Gene editing (103)
Generative AI (19)
Gene therapy (306)
GLP-1 (696)
Government (4132)
Grass and pollen (5)
Guidances (146)
Healthcare (15997)
Huntington's disease (24)
IgA nephropathy (29)
Immunology and inflammation (132)
Indications (27)
Infectious disease (2608)
Inflammatory bowel disease (135)
Inflation Reduction Act (8)
Influenza (52)
Intellectual property (89)
Interviews (523)
IPO (12523)
IRA (41)
Job creations (2579)
Job search strategy (1670)
Kidney cancer (11)
Labor market (23)
Layoffs (427)
Leadership (23)
Legal (5739)
Liver cancer (73)
Lung cancer (323)
Lymphoma (146)
Machine learning (8)
Management (51)
Manufacturing (268)
MASH (80)
Medical device (10587)
Medtech (10591)
Mergers & acquisitions (15651)
Metabolic disorders (679)
Multiple sclerosis (79)
NASH (23)
Neurodegenerative disease (101)
Neuropsychiatric disorders (31)
Neuroscience (1950)
NextGen: Class of 2025 (5525)
Non-profit (3975)
Now hiring (32)
Obesity (348)
Opinion (210)
Ovarian cancer (77)
Pain (89)
Pancreatic cancer (85)
Parkinson's disease (147)
Partnered (17)
Patents (225)
Patient recruitment (109)
Peanut (41)
People (50839)
Pharmaceutical (22)
Pharmacy benefit managers (11)
Phase I (18305)
Phase II (26167)
Phase III (19981)
Pipeline (1295)
Policy (139)
Postmarket research (2311)
Preclinical (7486)
Press Release (54)
Prostate cancer (100)
Psychedelics (37)
Radiopharmaceuticals (214)
Rare diseases (366)
Real estate (4091)
Recruiting (56)
Regulatory (19099)
Reports (26)
Research institute (2115)
Resumes & cover letters (356)
Rett syndrome (5)
RNA editing (3)
RSV (39)
Schizophrenia (76)
Series A (117)
Series B (77)
Service/supplier (3)
Sickle cell disease (52)
Special edition (12)
Spinal muscular atrophy (145)
Sponsored (28)
Startups (2731)
State (2)
Stomach cancer (14)
Supply chain (57)
Tariffs (36)
The Weekly (38)
Vaccines (643)
Venture capitalists (31)
Weight loss (231)
Women's health (26)
Worklife (17)
Date
Last 7 days (839)
Last 30 days (2616)
Last 365 days (28103)
2025 (10147)
2024 (30559)
2023 (34095)
2022 (44520)
2021 (47764)
2020 (46280)
2019 (39625)
2018 (30032)
2017 (26940)
2016 (25608)
2015 (29974)
2014 (22438)
2013 (18234)
2012 (19466)
2011 (20492)
2010 (18084)
Location
Africa (719)
Alabama (49)
Alaska (4)
Arizona (144)
Arkansas (11)
Asia (33603)
Australia (7025)
California (5260)
Canada (1847)
China (476)
Colorado (229)
Connecticut (220)
Delaware (139)
Europe (75152)
Florida (837)
Georgia (172)
Idaho (48)
Illinois (470)
India (23)
Indiana (277)
Iowa (7)
Japan (159)
Kansas (90)
Kentucky (19)
Louisiana (9)
Maine (49)
Maryland (800)
Massachusetts (3728)
Michigan (196)
Minnesota (300)
Mississippi (1)
Missouri (75)
Montana (21)
Nebraska (22)
Nevada (60)
New Hampshire (63)
New Jersey (1561)
New Mexico (20)
New York (1520)
North Carolina (803)
North Dakota (5)
Northern California (2309)
Ohio (168)
Oklahoma (5)
Oregon (26)
Pennsylvania (1178)
Puerto Rico (13)
Rhode Island (27)
South America (987)
South Carolina (21)
South Dakota (1)
Southern California (2042)
Tennessee (84)
Texas (807)
United States (19777)
Utah (174)
Virginia (137)
Washington D.C. (52)
Washington State (481)
West Virginia (3)
Wisconsin (42)
545,011 Results for "rezolute formerly known as antriabio".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Rezolute to Participate in Upcoming Investor Conferences - May 1, 2025
May 2, 2025
·
1 min read
Press Releases
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
May 5, 2025
·
5 min read
Press Releases
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
January 27, 2025
·
3 min read
Press Releases
Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors
March 27, 2025
·
3 min read
Press Releases
Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism (“HI”)
April 23, 2025
·
6 min read
Press Releases
Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference
January 31, 2025
·
1 min read
Breast cancer
AstraZeneca, Daiichi Sankyo’s ADC Wins First Approval Despite Mixed Data
Datroway, formerly known as Dato-DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
January 21, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
February 12, 2025
·
7 min read
Press Releases
FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
December 4, 2024
·
5 min read
Biotech Bay
Rezolute to Participate in the Jefferies Global Healthcare Conference
Rezolute, Inc. for serious metabolic and rare diseases, today announced that Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute, will participate in a fireside chat during the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 1:00 p.m. ET in New York City.
May 30, 2024
·
1 min read
1 of 54,502
Next
